Form 8-K · Current report
Bio-Techne 8-K, filed Sep 23, 2026
- Filed
- CIK
- 0000842023
- Accession no.
- 0001140361-26-037450
Summary
Bio-Techne shareholders approved the company's merger agreement with Merck KGaA, Darmstadt, Germany, at a special meeting, while a non-binding advisory proposal on merger-related executive compensation failed. Bio-Techne said it expects the transaction to close by late 2026 or early 2027, subject to remaining regulatory approvals, after the Hart-Scott-Rodino waiting period expired.
Key points
- Bio-Techne shareholders voted 121,929,544 for and 1,208,817 against approving the merger agreement, with 30,610 abstentions.
- The non-binding compensation advisory proposal received 25,912,275 votes for and 96,412,306 against, with 844,390 abstentions.
- The Hart-Scott-Rodino antitrust waiting period for the transaction expired on September 18, 2026.
- Bio-Techne expects the transaction to close by late 2026 or early 2027, subject to customary closing conditions and remaining regulatory approvals.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.07Submission of Matters to a Vote of Security Holders
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 23, 2026, Bio-Techne Corporation, a Minnesota corporation (“Bio-Techne”), held a special meeting of shareholders (the “Special Meeting”) to consider and vote on certain proposals related to the Agreement and Plan of Merger, dated as of June 25, 2026 (as it may be amended from time to time in accordance with its terms, the “Merger Agreement”), by and among Bio-Techne, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Parent”), and EMD Holdings NewCo, Inc., a Minnesota corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), providing that, on the terms and subject to the…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.